financetom
Business
financetom
/
Business
/
Coherent Fiscal Q1 Adjusted Earnings, Revenue Rise; Q2 Outlook Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coherent Fiscal Q1 Adjusted Earnings, Revenue Rise; Q2 Outlook Set
Nov 5, 2025 2:04 PM

04:39 PM EST, 11/05/2025 (MT Newswires) -- Coherent (COHR) reported fiscal Q1 adjusted earnings late Wednesday of $1.16 per diluted share, up from $0.67 a year earlier.

Analysts polled by FactSet expected $1.04.

Revenue for the three months ended Sept. 30 was $1.58 billion, up from $1.35 billion a year earlier.

Analysts surveyed by FactSet expected $1.54 billion.

For fiscal Q2, the company expects adjusted EPS of $1.10 to $1.30 on revenue of $1.56 billion to $1.70 billion. Analysts expect EPS of $1.12 on revenue of $1.56 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--CSW Industrials Raises Quarterly Dividend to $0.24 a Share, Payable Nov. 8 to Shareholders of Record as of Oct. 25
--CSW Industrials Raises Quarterly Dividend to $0.24 a Share, Payable Nov. 8 to Shareholders of Record as of Oct. 25
Oct 11, 2024
08:49 AM EDT, 10/11/2024 (MT Newswires) -- Price: 374.45, Change: +0.06, Percent Change: +0.02 ...
Moody's cuts Volkswagen's outlook to 'negative' due to operating weakness
Moody's cuts Volkswagen's outlook to 'negative' due to operating weakness
Oct 11, 2024
FRANKFURT (Reuters) - Rating agency Moody's has cut its outlook on Volkswagen to negative from stable, citing a deteriorating operating performance at Europe's top carmaker and expected challenges to turn the situation around. We expect VW's operating performance to be muted into 2025 driven by low volume growth globally including a weak domestic China and sluggish Western Europe, increasing price...
Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316
Acrivon Therapeutics Reports First Patient Dosed in Phase 1 Trial of ACR-2316
Oct 11, 2024
08:50 AM EDT, 10/11/2024 (MT Newswires) -- Acrivon Therapeutics ( ACRV ) said Friday that the first patient has been dosed in its phase 1 clinical trial evaluating ACR-2316, which is being developed to treat patients with solid tumors. The company said the trial will determine the maximal tolerated dose and recommended phase 2 monotherapy dose, characterization of the pharmacokinetic...
Gannett Reports Results of Early Participation in 2026 Notes Exchange Offer
Gannett Reports Results of Early Participation in 2026 Notes Exchange Offer
Oct 11, 2024
08:49 AM EDT, 10/11/2024 (MT Newswires) -- Gannett ( GCI ) on Friday reported the results of early participation in an exchange offer for holders of its outstanding 6% senior secured notes due 2026. The company said that at as of the early tender time of 5 pm ET on Thursday, about $40.4 million of the notes have been tendered...
Copyright 2023-2026 - www.financetom.com All Rights Reserved